Denali Therapeutics Inc.

DNLI ·Healthcare, Drug Manufacturers - General, United States

← 5Y 10Y MAX →

Cash Flow History

Operating Cash Flow Free Cash Flow CapEx Share-Based Compensation

Period	Operating Cash Flow	Free Cash Flow	CapEx	Share-Based Compensation
Mar 2017	$-18.8M	$-19.7M	$868.0K	$765.0K
Jun 2017	$-17.6M	$-18.1M	$569.0K	$1.1M
Sep 2017	$-21.9M	$-22.3M	$367.0K	$1.1M
Dec 2017	$-18.3M	$-19.4M	$1.1M	$1.5M
Mar 2018	$33.6M	$33.0M	$537.0K	$2.9M
Jun 2018	$-41.8M	$-42.4M	$572.0K	$4.7M
Sep 2018	$-34.8M	$-35.7M	$847.0K	$5.5M
Dec 2018	$93.2M	$91.7M	$1.4M	$5.6M
Mar 2019	$-30.3M	$-32.4M	$2.0M	$6.9M
Jun 2019	$-43.2M	$-53.4M	$10.3M	$13.7M
Sep 2019	$-30.4M	$-33.3M	$2.8M	$8.9M
Dec 2019	$-47.6M	$-50.4M	$2.8M	$8.9M
Mar 2020	$-54.5M	$-55.4M	$879.0K	$10.8M
Jun 2020	$-43.4M	$-43.7M	$315.0K	$12.5M
Sep 2020	$86.0K	$-620.0K	$706.0K	$13.3M
Dec 2020	$513.9M	$512.7M	$1.2M	$13.8M
Mar 2021	$-50.2M	$-53.0M	$2.8M	$21.0M
Jun 2021	$-54.2M	$-55.0M	$772.0K	$21.1M
Sep 2021	$-41.4M	$-43.3M	$1.9M	$21.0M
Dec 2021	$-65.5M	$-68.5M	$3.1M	$22.1M
Mar 2022	$-72.1M	$-76.2M	$4.0M	$26.1M
Jun 2022	$-42.9M	$-45.8M	$2.9M	$23.9M
Sep 2022	$-57.0M	$-63.1M	$6.1M	$24.6M
Dec 2022	$-72.7M	$-77.5M	$4.8M	$25.2M
Mar 2023	$-58.8M	$-61.6M	$2.8M	$28.1M
Jun 2023	$-113.2M	$-119.0M	$5.9M	$26.6M
Sep 2023	$-87.4M	$-89.4M	$2.1M	$27.5M
Dec 2023	$-98.7M	$-100.9M	$2.2M	$26.0M
Mar 2024	$-113.6M	$-115.8M	$2.2M	$27.8M
Jun 2024	$-91.2M	$-96.0M	$4.8M	$25.1M
Sep 2024	$-59.1M	$-63.0M	$3.9M	$24.9M
Dec 2024	$-83.7M	$-88.8M	$5.1M	$25.1M
Mar 2025	$-131.5M	$-136.5M	$5.1M	$25.2M
Jun 2025	$-75.3M	$-79.6M	$4.3M	$25.4M
Sep 2025	$-107.3M	$-105.9M	$-1.4M	$25.1M
Dec 2025	$-98.5M	$-100.1M	$1.5M	$24.0M
Mar 2026	$-131.2M	$-133.7M	$2.5M	$23.1M
Jun 2026	$-97.0M	$-97.8M	$805.0K	$22.9M